{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:49:24Z","timestamp":1790912964060,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.jtauto.2022.100148","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T02:19:23Z","timestamp":1644545963000},"page":"100148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Positioning of myositis-specific and associated autoantibody (MSA\/MAA) testing in disease criteria and routine diagnostic work-up"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-4200","authenticated-orcid":false,"given":"Carolien","family":"Bonroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Piette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2022.100148_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/13497413.2018.1481571","article-title":"Myositis an evolving spectrum of disease","volume":"41","author":"Barsotti","year":"2018","journal-title":"Immunol. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib5","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion Body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jtauto.2022.100148_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jtauto.2022.100148_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/BOR.0b013e328313bff4","article-title":"Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis","volume":"20","author":"Gunawardena","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jtauto.2022.100148_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/joim.12524","article-title":"Diagnosis and classification of idiopathic inflammatory myopathies","volume":"280","author":"Lundberg","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Damoiseaux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2022.100148_bib13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WCO.0000000000000855","article-title":"Where are we moving in the classification of idiopathic inflammatory myopathies?","volume":"33","author":"Tanboon","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jtauto.2022.100148_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","article-title":"Advances in serological diagnostics of inflammatory myopathies","volume":"29","author":"Benveniste","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jtauto.2022.100148_bib15","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 october 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jtauto.2022.100148_bib17","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jtauto.2022.100148_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.jtauto.2022.100148_bib19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jtauto.2022.100148_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine"},{"key":"10.1016\/j.jtauto.2022.100148_bib21","first-page":"668","article-title":"Classification criteria for polymyositis and dermatomyositis","volume":"22","author":"Tanimoto","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.jtauto.2022.100148_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MD.0000000000000222","article-title":"Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features","volume":"93","author":"Troyanov","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.jtauto.2022.100148_bib25","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40063","article-title":"Editorial: a new classification of adult autoimmune myositis","volume":"69","author":"Senecal","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib26","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000507","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jtauto.2022.100148_bib28","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1136\/annrheumdis-2017-212709","article-title":"Response to: '2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?' by Malaviya","volume":"77","author":"Lundberg","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.semarthrit.2019.12.001","article-title":"Performance of the new EULAR\/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort","volume":"50","author":"Barsotti","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2022.100148_bib30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/acr2.11061","article-title":"External validation and evaluation of adding MRI or extended myositis antibody panel to the 2017 EULAR\/ACR myositis classification criteria","volume":"1","author":"Luu","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jtauto.2022.100148_bib31","article-title":"Performance of the 2017 EULAR\/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies","author":"Casal-Dominguez","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jtauto.2022.100148_bib33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, Amsterdam, The Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jtauto.2022.100148_bib34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jtauto.2022.100148_bib35","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.3390\/diagnostics11122246","article-title":"Profiling of myositis specific antibodies and composite scores as an aid in the differential diagnosis of autoimmune myopathies","volume":"11","author":"Mahler","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.jtauto.2022.100148_bib36","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jtauto.2022.100148_bib37","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1136\/annrheumdis-2017-212915","article-title":"Detection of myositis-specific antibodies","volume":"78","author":"Vulsteke","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","article-title":"Diagnostic performance of a commercial immunoblot assay for myositis antibody testing","volume":"48","author":"Bundell","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.jtauto.2022.100148_bib39","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.55563\/clinexprheumatol\/3cuc1s","article-title":"Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathy","volume":"38","author":"Piette","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","article-title":"Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies","volume":"9","author":"Ronnelid","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2022.100148_bib42","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jtauto.2022.100148_bib43","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3389\/fimmu.2019.00848","article-title":"Comparison of three immunoassays for the detection of myositis specific antibodies","volume":"10","author":"Mahler","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2022.100148_bib44","doi-asserted-by":"crossref","first-page":"112661","DOI":"10.1016\/j.jim.2019.112661","article-title":"Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies","volume":"474","author":"Cavazzana","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jtauto.2022.100148_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jtauto.2022.100148_bib46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2019.05.002","article-title":"Anti-OJ autoantibodies: rare or underdetected?","volume":"18","author":"Vulsteke","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2022.100148_bib47","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/atm-20-5175","article-title":"Dermatomyositis autoantibodies: how can we maximize utility?","volume":"9","author":"Hodgkinson","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib48","first-page":"1048","article-title":"Distinct dermatomyositis populations are detected with different autoantibody assay platforms","volume":"37","author":"Fiorentino","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib49","doi-asserted-by":"crossref","first-page":"102425","DOI":"10.1016\/j.autrev.2019.102425","article-title":"Validation of anti-Mi2 autoantibody testing by line blot","volume":"19","author":"Pinal-Fernandez","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2022.100148_bib50","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/rheumatology\/kez092","article-title":"Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy","volume":"58","author":"Richards","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jtauto.2022.100148_bib51","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jtauto.2022.100148_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jim.2012.03.001","article-title":"Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis","volume":"379","author":"Bonroy","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jtauto.2022.100148_bib53","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/08916934.2021.1907842","article-title":"Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests","volume":"54","author":"Alkema","year":"2021","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jtauto.2022.100148_bib54","doi-asserted-by":"crossref","first-page":"100013","DOI":"10.1016\/j.jtauto.2019.100013","article-title":"Frequencies and clinical associations of myositis-related antibodies in The Netherlands: a one-year survey of all Dutch patients","volume":"2","author":"Platteel","year":"2019","journal-title":"J. Transl. Autoimmun"},{"key":"10.1016\/j.jtauto.2022.100148_bib55","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.semarthrit.2021.03.012","article-title":"Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: a single centre-experience and literature review: systematic review","volume":"51","author":"Van Horebeek","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2022.100148_bib56","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics"},{"key":"10.1016\/j.jtauto.2022.100148_bib57","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1136\/annrheumdis-2019-215967","article-title":"Response to: 'Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?' by Cavazzana et al","volume":"79","author":"Ronnelid","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib58","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1136\/annrheumdis-2018-213153","article-title":"Detection of myositis-specific antibodies: additional notes","volume":"78","author":"Mahler","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib59","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1136\/annrheumdis-2018-213320","article-title":"Detection of myositis-specific antibodies: additional notes","volume":"78","author":"Infantino","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib60","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib61","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/rheumatology\/key451","article-title":"Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis","volume":"58","author":"Infantino","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jtauto.2022.100148_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2022.100148_bib63","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41584-020-00522-w","article-title":"Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases","volume":"16","author":"Bossuyt","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib64","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the first international consensus on standardized Nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015","volume":"6","author":"Chan","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2022.100148_bib65","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cca.2011.06.041","article-title":"Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA","volume":"412","author":"Mahler","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jtauto.2022.100148_bib66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12026-017-8974-3","article-title":"Reflex testing of speckled cytoplasmic patterns observed in routine ANA HEp-2 indirect immunofluorescence with a multiplex anti-synthetase dot-blot assay: a multicentric pilot study","volume":"66","author":"Infantino","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jtauto.2022.100148_bib67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1179\/2295333714Y.0000000010","article-title":"Belgian recommendations on ANA, anti-dsDNA and anti-ENA antibody testing","volume":"69","author":"Van Blerk","year":"2014","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.jtauto.2022.100148_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2005.05.007","article-title":"From ANA to ENA: how to proceed?","volume":"5","author":"Damoiseaux","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2022.100148_bib69","first-page":"971","article-title":"Validation of a new screening strategy for anti-extractable nuclear antigen antibodies","volume":"27","author":"Van Praet","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jtauto.2022.100148_bib70","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1515\/cclm-2017-0905","article-title":"Screening for connective tissue disease-associated antibodies by automated immunoassay","volume":"56","author":"Willems","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib71","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/art.34380","article-title":"Prevalence and sociodemographic correlates of antinuclear antibodies in the United States","volume":"64","author":"Satoh","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2022.100148_bib72","doi-asserted-by":"crossref","first-page":"405956","DOI":"10.1155\/2014\/405956","article-title":"Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies","volume":"2014","author":"Musset","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jtauto.2022.100148_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13317-016-0075-0","article-title":"International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results","volume":"7","author":"Damoiseaux","year":"2016","journal-title":"Auto Immun. Highlights"},{"key":"10.1016\/j.jtauto.2022.100148_bib74","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13317-020-0127-3","article-title":"The perspective on standardisation and harmonisation: the viewpoint of the EASI president","volume":"11","author":"Damoiseaux","year":"2020","journal-title":"Auto Immun. Highlights"},{"key":"10.1016\/j.jtauto.2022.100148_bib75","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12026-015-8774-6","article-title":"Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study","volume":"64","author":"Picard","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jtauto.2022.100148_bib76","doi-asserted-by":"crossref","first-page":"655262","DOI":"10.3389\/fimmu.2021.655262","article-title":"Likelihood ratio approach and clinical interpretation of laboratory tests","volume":"12","author":"Fierz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2022.100148_bib77","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1515\/cclm-2018-0807","article-title":"Standardization and harmonization of autoimmune diagnostics","volume":"56","author":"Jacobs","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib78","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/jalm\/jfaa064","article-title":"Likelihood ratios as value proposition for diagnostic laboratory tests","volume":"5","author":"Fierz","year":"2020","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib79","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1515\/cclm-2017-1077","article-title":"Standardization of autoimmune testing \u2013 is it feasible?","volume":"56","author":"Monogioudi","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jtauto.2022.100148_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400304","article-title":"Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting","volume":"40","author":"Smolen","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2022.100148_bib81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13075-020-02210-2","article-title":"Studies Group Myositis Autoantibody Scientific Interest, the promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis","volume":"22","author":"Tansley","year":"2020","journal-title":"Arthritis Res. Ther."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909022000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909022000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:32:21Z","timestamp":1762903941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909022000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":81,"alternative-id":["S2589909022000090"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2022.100148","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positioning of myositis-specific and associated autoantibody (MSA\/MAA) testing in disease criteria and routine diagnostic work-up","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2022.100148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100148"}}